McDermott + Bull has successfully placed Jennifer Bright as Chief Financial Officer at enVVeno Medical. In this role, Jennifer will serve as a key member of the executive leadership team, working closely with the CEO Rob Berman, to oversee finance, accounting, investor relations, and capitalization strategy as the company transitions into a commercial-stage organization. Her responsibilities will include SEC reporting, capital markets activities, financial infrastructure development, and aligning the finance function to support enVVeno’s continued growth.
Jennifer is an accomplished financial executive with more than 25 years of experience leading finance organizations across both public and private companies, particularly in the medical technology and life sciences sectors. Most recently, she served as Chief Financial Officer at Biolase, where she led the company through a Chapter 11 reorganization and eventual sale. She brings extensive expertise in SEC compliance, investor relations, capital raising, financial strategy, and operational transformation. Jennifer earned her B.A. in Business Administration with an emphasis in Accounting from the University of Washington and is a Certified Public Accountant in California.
enVVeno Medical is focused on developing bioprosthetic solutions to treat venous disease, with its lead product, the VenoValve®, poised to become the first surgically implanted device for patients suffering from severe deep venous Chronic Venous Insufficiency (CVI). With anticipated FDA premarket approval in 2025, enVVeno is uniquely positioned to address a large unmet clinical need in a market with over 2 million affected individuals in the U.S. alone.
This executive search was led by McDermott + Bull Managing Partner + Co-Founder Chris Bull, Partner Jake Vander Zanden, and Director Julia Markward.